Close

Zogenix (ZGNX) Issues Positive Update on Post-Hoc Analysis of Zohydro ER

September 2, 2014 7:31 AM EDT Send to a Friend
Zogenix (Nasdaq: ZGNX) announced new post-hoc analysis data showing that the indicated 12-hour dose of Zohydro ER, (hydrocodone bitartrate) Extended-Release ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login